Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 12Completed 11Unknown 7Not yet recruiting 7Active not recruiting 5Terminated 3Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 2NETWORK 2INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Burkitt Lymphoma 1

Interventions

pembrolizumab 439Carboplatin 322Nivolumab 298Cyclophosphamide 286Specimen Handling 271Magnetic Resonance Spectroscopy 259Cisplatin 250Paclitaxel 249Radiotherapy 230Dexamethasone 184Biopsy 182Gemcitabine 180durvalumab 171atezolizumab 152Doxorubicin 141Rituximab 138Lenalidomide 136Ipilimumab 134Docetaxel 132Bevacizumab 132Radiation 121Capecitabine 120Oxaliplatin 116Etoposide 116Radiosurgery 113Fluorouracil 112Pemetrexed 109fludarabine 106venetoclax 102Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Maintenance × Clear all
NCT04542824 2026-05-05

EPCOREâ„¢ NHL-3

Genmab

Phase 1/2 Active not recruiting
78 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04881838 2026-03-19

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Children's Cancer Group, China

Phase 3 Active not recruiting
172 enrolled
Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02845882 2026-03-18

LBL-2016 for Children or Adolescents in China

Children's Cancer Group, China

Phase 3 Active not recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07199855 2025-09-30

Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia

Zhejiang University

Phase 2 Active not recruiting
24 enrolled
Lymphoid

Burkitt Lymphoma

NCT07094464 2025-07-30

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

Chinese PLA General Hospital

Phase 1 Active not recruiting
20 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡